GLRX2

Across TCGA pan-cancer cohorts, GLRX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLRX2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GLRX2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GLRX2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LSCC, CCRCC, and HNSC are the cancer types where GLRX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	III,IV	0.534	0.905	.015	14	view →
CCRCC	DFS	Quartile	III,IV	0.233	0.783	<.001	13	view →
HNSC	OS	Tertile	III,IV	0.621	1.000	.023	12	view →
LUAD	DFS	Median	III,IV	0.922	0.409	.024	5	view →
PDAC	DFS	Median	II,III,IV	0.631	0.229	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GLRX2–LSCC (OS)

Open the LSCC breakdown →